Incyte Corporation (INCY)
NASDAQ • Healthcare
Last close at November 18, 2026 at 21:00 UTC
Metrics Over Time
Where the Money Goes
Q3 2026In plain terms: out of every $100 in revenue, Incyte Corporation currently loses $50.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Feb 9
in 82 daysQ1 2027% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Incyte beat revenue expectations in the third fiscal quarter of 2026, based on preliminary results reported October 29, 2026, with revenue up 14.0% to about $1.6 billion, rising from $1.366 billion a year ago, and topping the $1.465 billion estimate (+6.3%). The quarter’s sales mix remained heavily concentrated in the United States, where revenue rose 13.8% to roughly $1.4 billion, while Europe increased 7.0% to about $107 million. Profitability was reflected in gross profit of about $1.4 billion alongside a gross margin of 93.0%. Cash flow was a notable swing point, with negative operating cash flow of roughly $675 million. Consensus for the next period calls for EPS of $1.89 on revenue of $1.533 billion.
About Incyte Corporation
Incyte Corporation develops and markets prescription therapies in biotechnology, with revenue of $5.1 billion in FY2025. Listed on the NASDAQ as INCY, the company combines commercial oncology and hematology drugs with a clinical pipeline and global marketing operations built around therapies it develops itself.
Today's Snapshot
INCY closed 1.1% below yesterday's close, in line with a weaker sector. Incyte hired Babar Bashir, a clinical-development executive, to lead blood-cancer research.
Trading Volume
Below 10d avg (1.4M)
1.2M
vs S&P 500 Today
Underperforming Market
-0.82%
Updated: November 18, 2026 at 21:25 UTC
INCY Headlines
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$110.50 - $119.67Sell
- RSI (14)47.66Neutral
- Stochastic %K (14, 3, 3)55.05Neutral
- MACD Level (12, 26)0.68Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.